Lecanemab’s PDUFA date for its potential accelerated approval is January 6th. The product could launch after its FDA approval. Now the discussion turns to what price it will be launched at, and whether it will eventually be reimbursed by CMS, the predominant payer for a product such as lecanemab.
With FDA Accelerated Approval Of Alzheimer’s Drug Lecanemab Likely January 6th, Discussion Turns To Price And Reimbursement
